Fig. 3
tlr mRNA expression levels in HUVECs stimulated with SSc-ICs, PAPS-ICs, SLE-ICs, and NHS-ICs. Endothelial cells were incubated with SSc-ICs, PAPS-ICs, SLE-ICs, or NHS-ICs (1:2 dilution). LPS (1 μg/ml), Poly I:C (1 μg/ml) and ODN CpG (5 μM) were used as positive controls. *p < 0.01; **p < 0.001; ***p < 0.0001 versus medium. a tlr2 (RQ) [mean ± SD]. LPS [8.8 ± 0.42] versus medium [1.06 ± 0.08] (p < 0.0001) versus NHS-ICs (p < 0.0001). ATA-ICs [12.50 ± 3.54] versus medium (p < 0.0001) and versus NHS-ICs [0.75 ± 0.63] (p < 0.0001). ACA-ICs [5.65 ± 0.78] versus medium (p < 0.01) versus NHS-ICs (p < 0.01). ARA-ICs [0.83 ± 0.09] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). Anti-Th/To-ICs [0.85 ± 0.23] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). PAPS-ICs [2.25 ± 0.21] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). SLE-ICs [1.15 ± 0.49] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). NHS-ICs [0.75 ± 0.63] versus medium (p = N.S.). b tlr3 (RQ) [mean ± SD]. Poly I:C [2.30 ± 0.28] versus medium [1.03 ± 0.04] (p < 0.0001) versus NHS-ICs (p < 0.0001). ATA-ICs [2.65 ± 0.21] versus medium (p < 0.0001) and versus NHS-ICs [1.15 ± 0.07] (p < 0.0001). ACA-ICs [2.5 ± 0.28] versus medium (p < 0.0001) versus NHS-ICs (p < 0.0001). ARA-ICs [0.85 ± 0.07] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). Anti-Th/To-ICs [0.80 ± 1.14] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). PAPS-ICs [1.75 ± 0.21] versus medium (p < 0.01) versus NHS-ICs (p < 0.01). SLE-ICs [0.30 ± 0.14] versus medium (p < 0.01) versus NHS-ICs (p < 0.001). NHS-ICs [1.15 ± 0.07] versus medium (p = N.S.). c tlr4 (RQ) [mean ± SD]. LPS [8.25 ± 0.35] versus medium [1.01 ± 0.02] (p < 0.0001) versus NHS-ICs (p < 0.0001). ATA-ICs [16.50 ± 2.12] versus medium (p < 0.0001) and versus NHS-ICs [1.15 ± 0.07] (p < 0.0001). ACA-ICs [3.65 ± 0.21] versus medium (p < 0.01) versus NHS-ICs (p < 0.0001). ARA-ICs [0.80 ± 0.14] versus medium (p = N.S.) versus NHS-ICs (p < 0.01). Anti-Th/To-ICs [0.70 ± 0.28] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). PAPS-ICs [1.85 ± 0.21] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). SLE-ICs [0.35 ± 0.17] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). NHS-ICs [1.21 ± 0.57] versus medium (p = N.S.). d tlr9 (RQ) [mean ± SD]. LPS [2.8 ± 0.14] versus medium [1.12 ± 0.03] (p < 0.001) versus NHS-ICs (p < 0.0001). ODNCpG [2.7 ± 0.28] versus medium (p < 0.001) versus NHS-ICs (p < 0.0001). ATA-ICs [1.25 ± 0.35] versus medium (p = N.S.) and versus NHS-ICs [0.75 ± 0.64] (p = N.S.). ACA-ICs [0.9 ± 0.2] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). ARA-ICs [1.4 ± 0.13] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). Anti-Th/To-ICs [2.20 ± 0.42] versus medium (p < 0.01) versus NHS-ICs (p < 0.001). PAPS-ICs [1.4 ± 0.12] versus medium (p = N.S.) versus NHS-ICs (p = N.S.). SLE-ICs [2.70 ± 0.28] versus medium (p < 0.001) versus NHS-ICs (p < 0.0001). NHS-ICs [0.85 ± 0.49] versus medium (p = N.S)